ArticleBreast cancer research : BCR2026
Pathogenic germline variants in BRCA1/2 are associated with a decreased number of hypomethylated rDNA copies.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLittle is known about the phenotypic impact of the enormous rDNA copy number (CN) variation among individuals. The rDNA CN appears to be stable across different tissues of the same individual, whereas many tumors exhibit consistent rDNA CN changes, compared to healthy tissue. Herein, we have analyzed rDNA CN in blood of healthy carriers of BRCA1/2 pathogenic variants (PV), who have a high risk of developing breast and ovarian cancer.
methodsUsing a combination of digital droplet PCR and deep bisulfite sequencing we have determined the absolute rDNA CN and the number of copies with a hypomethylated (≤ 10%) promoter region in healthy BRCA1 (N = 90) and BRCA2 (N = 71) PV carriers as well as in PV-negative controls (N = 146).
resultsAbsolute CN was comparable between groups. However, there was a significant and an almost significant difference, respectively, in hypomethylated rDNA CN between females carrying a BRCA1 (P = 0.023) or BRCA2 PV (P = 0.085), compared to controls. The effect appeared to be restricted primarily to younger women. PV carriers younger than 45 years (69 BRCA1, 47 BRCA2) exhibited approximately 10 hypomethylated copies less (P = 0.015 for BRCA1 and 0.150 for BRCA2) than age-matched controls (N = 98).
conclusionsOur results link germline BRCA1/2 PV to rDNA epigenetic regulation. We propose that the decreased number of hypomethylated, presumably active CN may contribute to cancer susceptibility in BRCA1/2 PV carriers, preceding tumor development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.